DNAmito is on the mission to personalize cancer treatment planning based on genomics.
PRODECIS is a clinical-grade decision support system for the personalized treatment of cancer. The AI-based predictive models are based on toxicity, tumor control, quality of life and cost-effectiveness. Prodecis uses multiple factors such as biological, genetic, clinical and imaging data to compare various treatment options. Prodecis helps radiation oncologists select the best treatment path for each patient.
MITOTx is The Next Generation Predictive DNA sequencing product currently under development: Saliva-based SNP / mitochondrial DNA test to assess the risk of radiation-induced toxicity.
The current clinical practice in radiation therapy does not differentiate the dose for each patient. The genetic test gives a reliable indication of the complication risk of radiation toxicity and thereby direct the patients to the type of radiation therapy that minimizes radiation to healthy tissue. It also indicates the possibility of a higher dose when the patient can tolerate it, thereby increasing the effectiveness of treatment.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 2225 E Bayshore Rd, Suite 200,netherlands
- Phone
- +1 650 687 0899
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- dnamito.com
- Keywords
- Fairfield.
- HQ
- Palo Alto, California
Dnamito Questions
Dnamito's helpline number is +1 650 687 0899
Dnamito's website is dnamito.com
Dnamito's LinkedIn profile is https://www.linkedin.com/company/dnamito
Dnamito has
4 employees.
View email and phone details for 4
employees at Dnamito.
Dnamito's industry is
Hospitals and Health Care
Dnamito's top competitors are
Alercell,
Mitochon Pharmaceuticals, Inc.,
Mdna Life Sciences,
Magle Biopharma,
Miradx,
Xinnate,
Dna Diagnostics Center | Eurofins,
Abliva Ab,
Motum.ai,
Tesis Biosciences.
Dnamito's categories are Hospitals and Health Care
Dnamito's founding year is 2015
